![No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/07/Sjogren_syndrome_2-350x250.jpg)
Iscalimab shows dose-dependent improvement among patients with active Sjögren’s disease
1. Isaclimab significantly improved disease activity at 150 mg and 600 mg doses. 2. Adverse events were comparable between cohorts ...
Tag: Sjögren’s Syndrome
Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European ...
#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Patient Basics: Sjögren’s Syndrome
Originally published by Harvard Health. What Is It? Sjögren’s (pronounced "show grins") syndrome is a chronic (or lifelong) condition that ...
No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]
1. After 24 weeks of treatment, hydroxychloroquine was no more effective than placebo in improving scores for dryness, pain, and ...
Autoantibodies may precede symptom onset in Sjögren’s Syndrome
Image: PD 1. 66% of patients with Sjögren’s Syndrome (SS) in this study had autoantibodies detected in the serum prior ...
